Eva Jäger

Medical University of Vienna

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Klaus Geißler

Klinik Hietzing

Peter Valent

Medical University of Vienna

Agnes Barna

Austrian Red Cross

LÖ

Leopold Öhler

St. Josef-Krankenhaus Wien

Ilse Schwarzinger

Medical University of Vienna

Sigrid Machherndl‐Spandl

Krankenhaus der Elisabethinen

Thomas Nösslinger

Hanusch Hospital

Michael Pfeilstöcker

Hanusch Hospital

Ulrich Jäger

Medical University of Vienna

Rajko Kušec

University of Zagreb

Cooperative Institutions

Medical University of Vienna

University of Vienna

Vienna General Hospital

Charles University

Comprehensive Cancer Center Vienna

Klinik Hietzing

Austrian Breast & Colorectal Cancer Study Group

Hanusch Hospital

Innsbruck Medical University

Ludwig Boltzmann Institute for Digital Health and Prevention

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

1 »Mahlzeit!«Einleitende Worte zu einer integrativen Grundhaltung

Vandenhoeck & Ruprecht eBooks (2023)

Eva Jäger

Download

10.13109/9783666634161.9

Cite

Citations (0)

Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience

Wiener klinische Wochenschrift (2014)

Wolfgang Füreder Andrea Paulitsch-Buckingham Werner Rabitsch Eva Jäger Ilse Schwarzinger

Aplastic anemia

Single Center

Savior sibling

10.1007/s00508-013-0484-2

Cite

Citations (7)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

Wiener klinische Wochenschrift (2016)

Wolfgang Füreder Sabine Cerny‐Reiterer Wolfgang R. Sperr Leonhard Müllauer Eva Jäger

Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5 patients with MDS or aplastic anemia (AA) evolving to MDS. Two patients with hypoplastic MDS (hMDS) showed a partial response (PR) to alemtuzumab. In both responding patients, a concomitant paroxysmal nocturnal hemoglobinuria (PNH) clone was detected before therapy. One responder relapsed after 15 months and underwent successful allogeneic stem cell transplantation. Both patients are still alive and in remission after 40 and 20 months, respectively. The other patients showed no response to alemtuzumab. One patient died from pneumonia 4 months after treatment. In summary, our data confirm that alemtuzumab is an effective treatment option for a subset of patients with MDS, even in the presence of a PNH clone.

Paroxysmal nocturnal hemoglobinuria

Aplastic anemia

CD52

Concomitant

clone (Java method)

10.1007/s00508-016-1091-9

Cite

Citations (4)

Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization

PLoS ONE (2011)

Eva Jäger Vincent H. J. van der Velden Jeroen G. te Marvelde Roland B. Walter Zvia Agur

Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute myeloid leukemia (AML). The optimal treatment schedule and optimal timing of GO administration relative to other agents remains unknown. Conventional pharmacokinetic analysis has been of limited insight for the schedule optimization. We developed a mechanism-based mathematical model and employed it to analyze the time-course of free and GO-bound CD33 molecules on the lekemic blasts in individual AML patients treated with GO. We calculated expected intravascular drug exposure (I-AUC) as a surrogate marker for the response to the drug. A high CD33 production rate and low drug efflux were the most important determinants of high I-AUC, characterizing patients with favorable pharmacokinetic profile and, hence, improved response. I-AUC was insensitive to other studied parameters within biologically relevant ranges, including internalization rate and dissociation constant. Our computations suggested that even moderate blast burden reduction prior to drug administration enables lowering of GO doses without significantly compromising intracellular drug exposure. These findings indicate that GO may optimally be used after cyto-reductive chemotherapy, rather than before, or concomitantly with it, and that GO efficacy can be maintained by dose reduction to 6 mg/m2 and a dosing interval of 7 days. Model predictions are validated by comparison with the results of EORTC-GIMEMA AML19 clinical trial, where two different GO schedules were administered. We suggest that incorporation of our results in clinical practice can serve identification of the subpopulation of elderly patients who can benefit most of the GO treatment and enable return of the currently suspended drug to clinic.

Gemtuzumab ozogamicin

Calicheamicin

10.1371/journal.pone.0024265

Cite

Citations (34)

5 Das Innere Team im Selbstgespräch zu Integrativer Beratung

Vandenhoeck & Ruprecht eBooks (2023)

Eva Jäger

Download

10.13109/9783666634161.82

Cite

Citations (0)

T-CELL VACCINATION VIA REVERSE ENGINEERING: TRANSIENT DISEASE

Journal of Biological Systems (1995)

Lee A. Segel Eva Jäger

The “reverse engineering” approach to modelling is applied to T-cell vaccination. The novelty here is the representation of the diseased state as a transient.

Transient (computer programming)

Reverse engineering

10.1142/s0218339095000411

Cite

Citations (6)

Strategies for ethical systems and organisations, and for empowering AI artists

The new real magazine. (2023)

Eva Jäger

At The New Real, we want to reflect and represent those at the forefront of art and AI – and to work with them to develop actionable strategies and signposts for practitioners. Here Eva Jäger, Curator of Arts Technologies at Serpentine, looks at ethical and relational business models, and emerging practices of artists. We wanted to know: What are the viable alternatives to current extractive AI business models, how can we achieve them, and do they work at scale? What are the common issues at the heart of these debates; what does the current and emerging generations of artists want; and should we even think about intelligent art through a business-lens? In short: How do we build ethical, fair and prosperous systems and organisations for art, audiences and artists?

10.2218/newreal.9252

Cite

Citations (0)

Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia

Leukemia Research Reports (2019)

Klaus Geißler Eva Jäger Michael Gurbisz

The correlation of molecular and phenotypic evolution in individual patients with chronic myelomonocytic leukemia (CMML) is poorly investigated. The longitudinal follow up of a CMML patient for more than 10 years illustrates that the emergence of clones harboring mutations in TET2, SRSF2, RUNX1, MPL, NRAS, and finally in multiple genes, respectively, was mirrored by thrombocytopenia, thrombocytosis, myeloproliferation and transformation into acute myeloid leukemia. Moreover, molecular aberrations of the RAS genes were associated with markedly increased spontaneous in vitro myeloid colony formation which has been shown to be a functional indicator of RAS pathway hyperactivation.

Chronic myelomonocytic leukemia

Thrombocytosis

10.1016/j.lrr.2019.100185

Cite

Citations (1)

Somebody is knocking at your door

Wege zum Menschen (2020)

Eva Jäger

This article presents the counseling with the inner team and the so-called “Ego States”. The focus is on integrating devalued and separated parts. After describing the aims and approaches in counseling with ego-states, the article ties these in with concrete biblical resources. Lastly, several vignettes from counseling practice with religious Christian clients complete the introduction to this work.

10.13109/weme.2020.72.1.55

Cite

Citations (1)

Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

Blood (2016)

Klaus Geißler Agnes Barna Eva Jäger Temeida Alendar Elmir Ljubuncic

Chronic myelomonocytic leukemia

Monocytosis

10.1182/blood.v128.22.3189.3189

Cite

Citations (1)